What TRIUMF Innovations does

TRIUMF Innovations Inc. is a private Vancouver-based company (founded 2008, mandate expanded April 2017) that operates as the commercialization arm of TRIUMF, Canada's national particle accelerator laboratory. It links cutting-edge particle-physics research to commercial markets through three channels: technology licensing, industry partnerships, and company creation from a portfolio of five spin-offs (ARTMS, Ideon, Micromatter, IKOMED, and D-Pace). Its core technology is built on TRIUMF's particle accelerator infrastructure, including the 520 MeV cyclotron (the largest in the world) and the TR-24 medical cyclotron at the IAMI facility, supporting medical isotope production (Tc-99m, Ga-68, Cu-64, Zr-89, Ac-225, F-18), proton/neutron irradiation testing services for aerospace electronics, neutron spectrometry for fusion diagnostics, and cosmic-ray muon tomography for mineral exploration. The IP and know-how base, partially cGMP-certified, includes the QUANTM Irradiation System licensed to ARTMS, muon-detection systems licensed to Ideon, and accelerator components licensed to D-Pace, all originally developed within TRIUMF's ~600-person research environment.

TRIUMF Innovations monetizes through a mix of licensing and royalty streams on out-licensed TRIUMF technologies, fee-for-service irradiation testing via the PIF/NIF facilities, professional services tied to industry R&D collaborations, management oversight of the CMIE Development Fund (backed by a $35M CAD Strategic Innovation Fund award), and equity participation in spin-off companies. Customer segments span hospitals and radiopharmaceutical firms (medical isotope demand), aerospace and defense companies (radiation-hardness testing), mining and natural resources firms (muon tomography), fusion energy companies (plasma diagnostics), and research institutions. Notable counterparties include MDA Robotics, Fusion Pharmaceuticals, Canadian Nuclear Laboratories, BWXT Medical, GE Healthcare, General Fusion, Telix Pharmaceuticals, Deerfield Management, and Quark Venture. The 18% of TRIUMF funding derived from commercialization activities, $52M raised across the five spin-offs, the $82.5M USD Telix/ARTMS exit, and a $400M federal capital infusion into the parent lab in 2024 underscore the scale and strategic significance of the commercialization platform.

Name

TRIUMF Innovations

Legal name

TRIUMF Innovations Inc.

Website

https://triumfinnovations.ca

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

TRIUMF Innovations is the private commercialization arm of TRIUMF, Canada's national particle accelerator laboratory, licensing accelerator-based technologies and creating spin-off companies in medical isotopes, radiation testing, and muon tomography for global industry and research partners.

Ownership category

akta.pro rank

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others

Revenue model

1. Technology Licensing and IP Management: Out-licensing TRIUMF technologies, providing technology transfer and licensing services to partner research institutions and industry
2. Company Creation and Spin-offs: Creating and supporting spin-off companies from TRIUMF technologies. Five successful spin-offs created (ARTMS, Ideon, Micromatter, IKOMED, D-Pace) with $52 million in seed and Series A & B financing raised
3. Industry Partnerships and Collaborations: Facilitating industry partnerships between TRIUMF researchers and private sector companies for joint R&D, product development, and commercialization
4. Irradiation Testing Services: Commercial irradiation services for electronics testing simulating space and terrestrial radiation environments, with commercial revenue increased by over 400% in recent years
5. Federal and Provincial Funding: Government funding including $35 million from Strategic Innovation Fund for CMIE, $400 million federal investment in TRIUMF, and various NSERC grants. 18% of TRIUMF's funding comes from commercialization activities

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

TRIUMF Innovations commercializes particle-accelerator-based technologies developed at TRIUMF, Canada's national particle accelerator laboratory. It does so through technology licensing, spin-off company creation and equity oversight, fee-based irradiation and medical isotope production services using TRIUMF's cyclotrons and Proton/Neutron Irradiation Facilities, and the Canadian Medical Isotope Ecosystem (CMIE) national platform that channels federal funding into radiopharmaceutical development. Its customer base consists of radiopharmaceutical companies, hospitals with medical cyclotrons, aerospace and electronics firms needing radiation testing, mining exploration companies, and fusion energy developers.

Product overview

TRIUMF Innovations serves as the commercialization arm of TRIUMF, Canada's national particle accelerator laboratory, operating a multi-faceted portfolio of products and services. The core offerings include medical isotope production via cyclotron facilities (TR-24 Medical Cyclotron, F-18, C-11, Ac-225, Sr-82, Ge-68, I-123), Irradiation Testing Services (proton and neutron beam testing for electronics), and the Canadian Medical Isotope Ecosystem (CMIE) development initiative. The portfolio also includes five successful spin-off companies: ARTMS QUANTM Irradiation System (cyclotron-based medical isotope production), Ideon Muon Tomography Platform (AI-powered subsurface imaging), Micromatter Target Foils, IKOMED AI-Guided X-ray Systems, and D-Pace Accelerator Components. The organization also provides neutron spectrometer technology for fusion diagnostics and entrepreneurship training programs through UBC partnership.

Differentiator

Problem solved

Functional benefit

Products and services

• TR-24 Medical Cyclotron State-of-the-art commercial cyclotron at the Institute for Advanced Medical Isotopes (IAMI) producing medical isotopes critical for Canadian health research and clinical use, including Ac-225. For radiopharmaceutical developers and clinical researchers.
• Cyclotron Isotope Production (F-18, C-11, Ac-225, Sr-82, Ge-68, I-123) Production of radioisotopes using TRIUMF's 13 MeV and 24 MeV cyclotrons for PET and SPECT scans, and the 520 MeV cyclotron for targeted alpha therapy applications. For radiopharmaceutical developers, hospitals, and clinical researchers.
• Irradiation Testing Services (PIF & NIF) Proton and Neutron Irradiation Facilities (PIF & NIF) providing low-intensity energetic proton and neutron beams to simulate radiation exposures for accelerated testing of electronics in space, air, or ground environments. For aerospace and electronics manufacturers.
• ARTMS QUANTM Irradiation System Technology enabling hospitals to use existing medical cyclotrons for production of medical isotopes including Technetium-99m, Gallium-68, Copper-64, and Zirconium-89 for diagnostic imaging. For hospitals with medical cyclotrons and radiopharmaceutical manufacturers.
• Ideon Muon Tomography Platform World-first discovery platform using cosmic-ray muon tomography with proprietary detectors, imaging systems, and AI to provide subsurface imaging up to 1 km depth for mineral exploration. For mining and mineral exploration companies.
• Micromatter Target Foils Thin carbon foils, accelerator target foils, and X-ray fluorescence calibration standards with applications in air quality monitoring, trace element detection, and particle accelerators. For research labs and accelerator operators.
• IKOMED AI-Guided X-ray Systems AI-guided X-ray shuttering system protecting patients and medical staff during minimally-invasive procedures, and in-development device for emphysema treatment using radiofrequency. For hospitals and surgical centers.
• D-Pace Accelerator Components Beamline systems, beam diagnostic devices, and ion sources for research, industrial, and commercial accelerator systems, providing H-, D-, C2-, and other ions. For accelerator manufacturers and operators.
• Canadian Medical Isotope Ecosystem (CMIE) Development Fund Nation-wide initiative co-led with Centre for Probe Development and Commercialization, backed by up to $35M from Strategic Innovation Fund to unite stakeholders and accelerate medical isotope technology development and commercialization through the CMIE Development Fund. For Canadian startups, research institutions, and industry partners in medical isotopes.
• Ultra-fast Neutron Spectrometer System Ultra-fast neutron spectrometer system developed with General Fusion to measure plasma temperatures at fusion conditions over 100 million degrees Celsius, tagging neutron interactions every nanosecond. For fusion energy developers.

Quantifiable outcome

• 5 successful spin-off companies created with $52M in financing raised
• +3 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature4 records

Partnerships

18 partnerships are on record, tiered strategic, minor, flagship and core.

• General FusionstrategicStrategic or Co-development Partner · 27 March 2024NSERC Alliance grant collaboration to develop ultra-fast neutron spectrometer system for General Fusion's LM26 fusion demonstration machine. $800,000 over four years to measure plasma temperatures at fusion conditions exceeding 100 million degrees Celsius.
• Simon Fraser UniversityminorStrategic or Co-development Partner · 27 March 2024Partner in neutron spectrometer project with General Fusion, designing and implementing a dedicated neutron test facility at TRIUMF.
• Université de SherbrookeminorStrategic or Co-development Partner · 27 March 2024Developing and fabricating new Canadian single photon detection technology for the upgraded neutron spectrometer system to be installed on General Fusion's near-commercial machine.
• Telix PharmaceuticalsflagshipStrategic or Co-development Partner · 11 March 2024Telix Pharmaceuticals acquired ARTMS Inc. for $82.5M USD, including ARTMS' advanced cyclotron-based isotope production platform, manufacturing plant, and stockpile of ultra-pure rare metals. This is the largest acquisition of a TRIUMF spin-off company.
• Centre for Probe Development and Commercialization (CPDC)coreStrategic or Co-development Partner · 27 June 2023Co-leading the Canadian Medical Isotope Ecosystem (CMIE), a national platform backed by $35 million from the Strategic Innovation Fund. CMIE aims to advance medical isotope production, R&D investment, collaboration, technology adoption, and training to enable Canada to lead in medical isotope innovation.
• Bruce PowercoreStrategic or Co-development Partner · 27 June 2023CMIE partner providing infrastructure and support for medical isotope production and development in Canada.
• McMaster UniversitycoreStrategic or Co-development Partner · 27 June 2023CMIE partner with McMaster Nuclear Reactor as part of national platform to accelerate medical isotope development in Canada.
• Dual FluidstrategicStrategic or Co-development Partner · 10 March 2023MOU with Canadian-German nuclear technology company to advance Small Modular Reactor (SMR) development based on Dual Fluid technology. Collaboration leverages TRIUMF's Proton and Neutron Irradiation Facilities and metallurgical testing capabilities.
• Fusion PharmaceuticalscoreStrategic or Co-development Partner · 16 December 2020Collaboration for development, production, and supply of actinium-225. Fusion provides funding for TRIUMF to upgrade Ac-225 production infrastructure; receives preferred access and pricing to the resulting isotope for use in their radiopharmaceutical development.
• Centre for Drug Research and Development (CDRD)coreStrategic or Co-development Partner · 2 April 2019Partnership to advance and commercialize promising research in novel radiopharmaceuticals. Combines R&D, manufacturing, and commercialization strengths to develop innovative personalized cancer treatments using targeted alpha therapy.
• Canadian Nuclear Laboratories (CNL)coreStrategic or Co-development Partner · 27 September 2018Strategic partnership for production of actinium-225, a rare medical isotope with potential for groundbreaking cancer therapies. TRIUMF produces Ac-225 using its high-energy cyclotron; CNL processes it at Chalk River Laboratories. Successfully completed first joint production run in October 2019.
• GE HealthcarecoreStrategic or Co-development Partner · 10 September 2017ARTMS partnered with GE Healthcare around the QUANTM99 Irradiation System for radioisotope production. Partnership includes installation of Europe's first QUANTM system and research into expanding isotopes on GE's PETtrace 800 platform of medical cyclotrons.
• BWXT MedicalcoreStrategic or Co-development PartnerCommercial agreements for production and supply of actinium-225 ('the rarest drug on earth') to researchers and patients around the world.
• ImaginAbminorStrategic or Co-development PartnerARTMS partnered with ImaginAb for innovative manufacture of 89Zr CD8 ImmunoPET agent using ARTMS' high-power technology to enhance production of ImaginAb's proprietary antibody.
• POINT BiopharmaminorStrategic or Co-development PartnerARTMS collaboration with POINT Biopharma and Canadian Molecular Imaging Probe Consortium for Health Canada submission on Gallium-68 production.
• Canadian Nuclear Isotope CouncilstrategicStrategic or Co-development PartnerTRIUMF joined CNIC to strengthen national capacity in radioisotope and radiopharmaceutical research and education, and to advance benefits of medical isotopes in diagnosing and treating life-threatening illnesses.
• Buckley SystemsminorStrategic or Co-development PartnerElectromagnet manufacturer purchased 50% stake in D-Pace in 2014, enabling collaboration that has developed and commercialized approximately a dozen new products for the particle accelerator market.
• University of British ColumbiacoreStrategic or Co-development PartnerTRIUMF is hosted on UBC campus; partnered with UBC and BC Cancer for Institute for Advanced Medical Isotopes (IAMI) development. TRIUMF is a joint venture owned by 21 member universities.

Scale indicators17 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Canadian Nuclear Laboratories: Canada's federal nuclear science laboratory and a core strategic partner on Ac-225 production. CNL operates Chalk River Laboratories and collaborates with TRIUMF on actinium-225 processing — a comparable government nuclear research entity engaged in isotope production and nuclear materials R&D.
• ARTMS Inc. (Telix Pharmaceuticals): TRIUMF Innovations' largest spin-off, founded by TRIUMF scientists, commercializing the QUANTM Irradiation System for cyclotron-based medical isotope production. Acquired by Telix Pharmaceuticals in March 2024 for $82.5M USD; provides the closest internal benchmark for TI's commercialization outcomes.
• Ideon Technologies: TRIUMF spin-off commercializing cosmic-ray muon tomography with AI for subsurface mineral exploration. Directly comparable as a TI-incubated company demonstrating the same commercialization model applied to a non-medical vertical.
• SHINE Medical Technologies: U.S.-based medical isotope producer using alternative production routes (fusion-based neutron generators) to address Tc-99m and other isotope shortages. Directly comparable mission — solving medical isotope supply chain vulnerability — and a direct competitor to TI/ARTMS technology.
• NorthStar Medical Radioisotopes: U.S. commercial medical isotope producer focused on non-uranium-based Mo-99/Tc-99m production. Directly comparable as a privately-held commercial-stage medical isotope producer targeting the same supply-chain-replacement opportunity that ARTMS was built to address.

Broad incumbents

• Telix Pharmaceuticals: Global radiopharmaceutical company and acquirer of ARTMS. While much larger and focused on finished radiopharmaceuticals rather than isotope production technology, Telix represents the strategic acquirer/customer archetype that TI's spin-offs increasingly interact with as commercial-stage entities.
• GE HealthCare: Global medical imaging and cyclotron manufacturer; ARTMS' QUANTM system integrates onto GE's PETtrace 800 platform, making GE both partner and incumbent competitor with substantially greater scale in PET/SPECT imaging infrastructure.
• IBA (Ion Beam Applications): Belgian global leader in cyclotron manufacturing, proton therapy, and radioisotope production. Operates in the same isotope production and accelerator technology space as TRIUMF/D-Pace but with substantially greater commercial scale and global footprint.
• BWX Technologies: U.S. nuclear technology manufacturer with a medical isotopes division (BWXT Medical) that is a commercial partner of TRIUMF Innovations on Ac-225 supply. Comparable as an incumbent in nuclear medicine isotopes and a customer/competitor in sealed source manufacturing.

Regional players

• Cyclotek: Australian radiopharmaceutical manufacturer producing PET and SPECT tracers using cyclotrons. Comparable as a privately-held regional radiopharma producer, though operating in a different geography from TRIUMF Innovations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/TRIUMFInno

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TRIUMF Innovations